VivoSeq
Other

Meniere Disease

8

Pipeline Programs↗

3

Active Trials↗

7

Companies Involved↗

Meniere disease is an early-stage landscape with 8 programs across 7 companies. The most active players are Eli Lilly, Sound Pharmaceuticals, Incorporated, Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 5 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

35/100

Pipeline Velocity

6/100

Mech. Concentration

40/100

Completion Rate

75/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

1 program

Phase 3S

Sound Pharmaceuticals, Incorporated

2 programs

Phase 3P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

ApprovedNovartis logo

Novartis

1 program

ApprovedPfizer logo

Pfizer

1 program

ApprovedP

Parkedale

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

7

clinical trials

Completed3 · 43%
Recruiting2 · 29%
Withdrawn1 · 14%
Active, not recruiting1 · 14%

Clinical Trials

Trial Activity

7 trials

Laser Acupuncture for Meniere Disease
Recruiting·—·Phase 2·NCT06544434·324 enrolled
Deep Phenotyping of Hearing Instability Disorders: Cohort Establishment, Biomarker Identification, Development of Novel Phenotyping Measures, and Discovery of Therapeutic Targets
Recruiting·National Institute on Deafness and Other Communication Disorders (NIDCD)·N/A·NCT04806282·210 enrolled
Open-Label Study of SPI-1005 for the Treatment of Meniere's Disease
Active, not recruiting·SSound Pharmaceuticals, Incorporated·Phase 3·NCT06859788·200 enrolled
Transcutaneous Auricular Vagus Nerve Stimulation for Meniere Disease
Completed·—·N/A·NCT06544590·77 enrolled
Phase 1b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of SPI-1005 in Meniere's Disease
Completed·SSound Pharmaceuticals, Incorporated·Preclinical·NCT02603081·40 enrolled
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of SPI-1005 in Meniere's Disease and Open Label Extension Study to Evaluate the Chronic Safety of SPI-1005
Completed·SSound Pharmaceuticals, Incorporated·Phase 3·NCT04677972·254 enrolled
Unilateral Meniere Disease: Can Double Dose Gadolinium and Delayed Imaging Make the Diagnosis?
Withdrawn·EEmory University·N/A·NCT02371798

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)